Notably, the EGFR tyrosine kinase inhibitor resistance pathway was significantly enriched in the youth group (Figure 5B), implying that the young lung cancer group was easier to get EGFR-TKI resistance. This evidence concerns the gene EGFR and lung carcinoma.